<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729556</url>
  </required_header>
  <id_info>
    <org_study_id>EC 19310-20</org_study_id>
    <nct_id>NCT04729556</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Sericin-chitosan Cream in Healthy Volunteers</brief_title>
  <official_title>Safety Evaluation of a Film-forming Cream Containing Sericin and Chitosan for Pressure Sore Treatment in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, active-controlled clinical trial was conducted to evaluate safety&#xD;
      of sericin-chitosan cream in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, active-controlled clinical trial was conducted to initially&#xD;
      evaluate safety of sericin-chitosan cream in comparison with a commercially available cream&#xD;
      containing dimethicone for pressure sore treatment in healthy volunteers. The results of this&#xD;
      study provided preliminary safety profile of sericin-chitosan cream before conducting the&#xD;
      further clinical trial in specific population (pateints with early-stage pressure sore).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin erythema index</measure>
    <time_frame>17 days</time_frame>
    <description>Erythema index will be measured using Cutometer (Mexameter). There is no unit. Higher value mean higher risk of post inflammatory reaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin melanin index</measure>
    <time_frame>17 days</time_frame>
    <description>Melanin index will be measured using Cutometer (Mexameter). There is no unit. Higher value mean higher risk of post inflammatory reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual skin irritation</measure>
    <time_frame>17 days</time_frame>
    <description>Photographs of the contact skin area will be used for evaluating the presences and severity of skin irritation (rash, edema, papules, vesicles, and bullae) by dermatologists.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-report topical side effects: rash, edema, vesicles, and itching</measure>
    <time_frame>17 days</time_frame>
    <description>Participants will be asked to self-monitor topical side effects: rash, edema, vesicles, and itching (if any), and then inform the investigators.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Pressure Sore</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Sericin and chitosan cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A flim-forming cream containing sericin and chitosan cream. Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavilon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control is a commercial cream containing dimethicone as the substance forms a durable, thin, and transparent film. The cream is used as a moisturizer to prevent the skin against irritation, dryness, and pressure ulcers.&#xD;
Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sericin and chitosan cream</intervention_name>
    <description>A novel film-forming cream containing sericin and chitosan</description>
    <arm_group_label>Cavilon</arm_group_label>
    <arm_group_label>Sericin and chitosan cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers at the age of 20 - 65 years&#xD;
&#xD;
          -  voluntarily sign inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with chronic skin conditions (e g. eczema and psoriasis) and&#xD;
             immunocompromised diseases&#xD;
&#xD;
          -  Allergic to silk sericin and chitosan, and dimethicone&#xD;
&#xD;
          -  Received immunosuppressive therapy, antihistamine, and corticosteroid drugs two weeks&#xD;
             before study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity</name>
      <address>
        <city>Bangkok</city>
        <zip>10310</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Pornanong Aramwit, Pharm.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pressure Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chitosan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

